Early Inhaled Budesonide for the Prevention of Bronchopulmonary Dysplasia.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  New England Journal of Medicine

• Publication date

  2015-10-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMoa1501917PMID 26465983
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early administration of inhaled corticosteroids for preventing chronic lung disease in very low birth weight preterm neonates.

  2017cited by this paper
• Oxygen Saturation and Outcomes in Preterm Infants

  2014cited by this paper
• Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.

  2014cited by this paper
• Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: a case-control follow-up at school age.

  2014cited by this paper
• Oxygen saturation and outcomes in preterm infants.

  2013cited by this paper
• Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.

  2012cited by this paper
• What is BPD in 2012 and what will BPD become?

  2012cited by this paper
• A SAS® macro implementation of a multiple comparison post hoc test for a Kruskal-Wallis analysis

  2011cited by this paper
• Targeting Inflammation to Prevent Bronchopulmonary Dysplasia: Can New Insights Be Translated Into Therapies?

  2011cited by this paper
• Target ranges of oxygen saturation in extremely preterm infants.

  2010cited by this paper
• Neonatal Outcomes of Extremely Preterm Infants From the NICHD Neonatal Research Network

  2010cited by this paper
• Rates of Bronchopulmonary Dysplasia in Very Preterm Neonates in Europe: Results from the MOSAIC Cohort

  2010cited by this paper
• Aerosol delivery to ventilated newborn infants: historical challenges and new directions

  2010cited by this paper
• Newborn-care training and perinatal mortality in developing countries.

  2010cited by this paper
• Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants.

  2009cited by this paper
• The Neonatal European Study of Inhaled Steroids (NEUROSIS): An EU-Funded International Randomised Controlled Trial in Preterm Infants

  2009cited by this paper
• Chronic lung disease after premature birth.

  2008cited by this paper
• Chronic lung disease after premature birth.

  2007cited by this paper
• Postdischarge Infant Mortality Among Very Low Birth Weight Infants: A Population-Based Study

  2007cited by this paper
• Caffeine therapy for apnea of prematurity.

  2006cited by this paper
• Respiratory function at age 8–9 years in extremely low birthweight/very preterm children born in Victoria in 1991–1992

  2006cited by this paper
• Contribution of inflammation to lung injury and development

  2006cited by this paper
• The international classification of retinopathy of prematurity revisited

  2005cited by this paper
• The International Classification of Retinopathy of Prematurity revisited.

  2005cited by this paper
• Impact of bronchopulmonary dysplasia, brain injury, and severe retinopathy on the outcome of extremely low-birth-weight infants at 18 months: results from the trial of indomethacin prophylaxis in preterms.

  2003cited by this paper
• Safety, Reliability, and Validity of a Physiologic Definition of Bronchopulmonary Dysplasia

  2003cited by this paper
• New Insights into the Pathogenesis of Pulmonary Inflammation in Preterm Infants

  2001cited by this paper
• Postnatal glucocorticoid therapy for prevention of bronchopulmonary dysplasia: routes of administration compared.

  2001cited by this paper
• A multicenter, randomized open study of early corticosteroid treatment (OSECT) in preterm infants with respiratory illness: comparison of early and late treatment and of dexamethasone and inhaled budesonide.

  2001cited by this paper
• Early administration of inhaled corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.

  2000cited by this paper
• Outbreak of extended spectrum β lactamase producingKlebsiella pneumoniae in a neonatal unit

  1999cited by this paper
• Randomised controlled study of early use of inhaled corticosteroid in preterm infants with respiratory distress syndrome

  1999cited by this paper
• Bronchoalveolar oxyradical inflammatory elements herald bronchopulmonary dysplasia.

  1996cited by this paper
• Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia

  1996cited by this paper
• Cranial ultrasound prediction of disabling and nondisabling cerebral palsy at age two in a low birth weight population.

  1995cited by this paper

• Automatic versus manual control of oxygen and neonatal clinical outcomes in extremely preterm infants: a multicentre, parallel-group, randomised, controlled, superiority trial.

  2026cites this paper
• Evidence-based early-post natal approaches to limiting pulmonary disease in extremely low birth weight infants.

  2026cites this paper
• Ciclesonide shows a lung-protective effect in neonatal hyperoxia-exposed rats

  2025cites this paper
• Budesonide and hydrocortisone have differential effects on lung and brain in ventilated preterm lambs

  2025cites this paper
• Does intratracheal budesonide mixed with surfactant increase survival without bronchopulmonary dysplasia in extremely preterm infants?

  2025cites this paper
• EBNEO Commentary: Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants. The PLUSS Randomized Clinical Trial

  2025cites this paper
• Longitudinal transcriptomic analysis of the hyperoxia-exposed preterm rabbit as a model of BPD

  2025cites this paper
• Negative Results in Neonatal Trials: Clinical Lessons and Future Directions – A Narrative Review

  2025cites this paper
• Influence of antenatal steroids on the effect of early inhaled postnatal corticosteroids: a post-hoc analysis of the NEuroSIS trial

  2025cites this paper
• Current and Emerging Therapies for Prevention and Treatment of Bronchopulmonary Dysplasia in Preterm Infants

  2025cites this paper
• Inhaled and Systemic Steroids for Bronchopulmonary Dysplasia: Targeting Inflammation and Oxidative Stress

  2025cites this paper
• Intratracheal instillation of corticosteroids combined with surfactant for preventing chronic lung disease in preterm infants

  2025cites this paper
• Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.

  2024cites this paper
• Point prevalence, characteristics and treatment variations for preterm infants with bronchopulmonary dysplasia in China: a ‘snapshot’ study

  2024cites this paper
• Prevention of Inflammatory Disorders in the Preterm Neonate: An Update with a Special Focus on Bronchopulmonary Dysplasia

  2024cites this paper
• Estimating the effect of diuretics and inhaled corticosteroids for evolving bronchopulmonary dysplasia in preterm infants.

  2024cites this paper
• Prophylactic low-dose hydrocortisone in neonates born extremely preterm: current knowledge and future challenges

  2024cites this paper
• Prescribing practices of inhaled corticosteroids for premature infants in the neonatal intensive care unit

  2024cites this paper
• Outcomes of postnatal systemic corticosteroids administration in ventilated preterm newborns: a systematic review of randomized controlled trials

  2024cites this paper
• Advanced Diagnostics of Respiratory Distress Syndrome in Premature Infants Treated with Surfactant and Budesonide through Computer-Assisted Chest X-ray Analysis

  2024cites this paper
• Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews.

  2024cites this paper
• Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: A systematic review and meta-analysis.

  2024cites this paper
• Strategies for the prevention of bronchopulmonary dysplasia

  2024cites this paper
• Commonly used medications for respiratory and cardiovascular support in neonates: Evidence, knowledge gaps, and future perspectives

  2024cites this paper
• Complex roles of TGF-β signaling pathways in lung development and bronchopulmonary dysplasia

  2023cites this paper
• Montelukast Sodium to Prevent and Treat Bronchopulmonary Dysplasia in Very Preterm Infants: A Quasi-Randomized Controlled Trial

  2023cites this paper
• Budesonide and surfactant combination for treatment of respiratory distress syndrome in preterm neonates and evaluation outcomes

  2023cites this paper
• Tracheomalacia Reduces Aerosolized Drug Delivery to the Lung

  2023cites this paper
• The prevention and management strategies for neonatal chronic lung disease

  2023cites this paper
• Strengthening Reporting of Neonatal Trials.

  2023cites this paper
• Management of bronchopulmonary dysplasia in Japan: A nationwide survey.

  2023cites this paper
• Postnatal corticosteroid exposure in very preterm infants: A French cohort study

  2023cites this paper
• Trends, Characteristic, and Outcomes of Preterm Infants Who Received Postnatal Corticosteroid: A Cohort Study from 7 High-Income Countries

  2023cites this paper
• Role of Postnatal Corticosteroids in the Treatment or Prevention of Bronchopulmonary Dysplasia

  2023cites this paper
• Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial

  2023cites this paper
• Outpatient management of established bronchopulmonary dysplasia: An update.

  2023cites this paper
• Respiratory management and outcomes in high-risk preterm infants with development of a population outcome dashboard

  2023cites this paper
• Postnatal Corticosteroids To Prevent Bronchopulmonary Dysplasia.

  2023cites this paper
• Association Between Enteral Supplementation With High-Dose Docosahexaenoic Acid and Risk of Bronchopulmonary Dysplasia in Preterm Infants

  2023cites this paper
• Predictors of extubation outcomes among extremely and very preterm infants: a retrospective cohort study

  2022cites this paper
• Postnatal Corticosteroids to Prevent or Treat Chronic Lung Disease Following Preterm Birth.

  2022cites this paper
• Respiratory support of infants born at 22-24 weeks of gestational age.

  2022cites this paper
• Automated prediction of extubation success in extremely preterm infants: the APEX multicenter study

  2022cites this paper
• Moving Bronchopulmonary Dysplasia Research from the Bedside to the Bench.

  2022cites this paper
• Pharmacotherapy in Bronchopulmonary Dysplasia: What Is the Evidence?

  2022influential citation
• Thresholds for blood transfusion in extremely preterm infants: A review of the latest evidence from two large clinical trials

  2022cites this paper
• The benefits, limitations and opportunities of preclinical models for neonatal drug development

  2022cites this paper
• Postnatal corticosteroid use for prevention or treatment of bronchopulmonary dysplasia in England and Wales 2012–2019: a retrospective population cohort study

  2022cites this paper
• Inhaled Corticosteroid Exposure in Hospitalized Infants with Bronchopulmonary Dysplasia

  2021cites this paper
• Inhaled Pharmacotherapy for Neonates: A Narrative Review

  2021cites this paper
• Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part II. Inhaled corticosteroids alone or in combination with surfactants

  2021cites this paper
• Potential therapeutic role of budesonide to reduce COVID-19 severity

  2021cites this paper
• Effectiveness and safety of early combined utilization of budesonide and surfactant by airway for bronchopulmonary dysplasia prevention in premature infants with RDS: A meta‐analysis

  2021cites this paper
• Inhaled Budesonide in Neonatal Respiratory Distress Syndrome of Near-Term Neonates: A Randomized, Placebo-Controlled Trial.

  2021cites this paper
• Bronchopulmonary dysplasia

  2021cites this paper
• Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part I. systemic corticosteroids

  2021cites this paper
• Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia

  2021cites this paper
• Evidence for the Management of Bronchopulmonary Dysplasia in Very Preterm Infants

  2021cites this paper
• Oxygen Toxicity to the Immature Lung—Part II: The Unmet Clinical Need for Causal Therapy

  2021cites this paper
• Impact of early respiratory care for extremely preterm infants.

  2021cites this paper
• Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies

  2021cites this paper
• An Update on the Prevention and Management of Bronchopulmonary Dysplasia

  2021cites this paper
• Lipid enemas for meconium evacuation in preterm infants – a retrospective cohort study

  2021cites this paper
• Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging

  2021cites this paper
• Cognitive and academic outcomes of children born extremely preterm.

  2021cites this paper
• Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia

  2021cites this paper
• Rates of Bronchopulmonary Dysplasia Following Implementation of a Novel Prevention Bundle

  2021cites this paper
• Efficacy of intratracheal budesonide-surfactant combined therapy in surfactant-insufficient rat lungs with lipopolysaccharide insult

  2021cites this paper
• Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

  2021cites this paper
• Intra‐tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants

  2021cites this paper
• Bronchopulmonary Dysplasia

  2021cites this paper
• Aerosol drug delivery to spontaneously-breathing preterm neonates: lessons learned

  2021cites this paper
• Epidemiology, aetiology, prevention, diagnosis, management and complications of BPD

  2021cites this paper
• The Intertemporal Role of Respiratory Support in Improving Neonatal Outcomes: A Narrative Review

  2021cites this paper
• Budesonide mixed with surfactant did not affect neurodevelopmental outcomes at 6 or 18 months corrected age in observational cohorts

  2021cites this paper
• Medication Use in the Neonatal Intensive Care Unit and Changes from 2010-2018.

  2021cites this paper
• Eligibility Criteria and Representativeness of Randomized Clinical Trials That Include Extremely Premature Infants: A Systematic Review.

  2021cites this paper
• Phenotypes of Bronchopulmonary Dysplasia

  2020cites this paper
• Montelukast improves bronchopulmonary dysplasia by inhibiting epithelial‑mesenchymal transition via inactivating the TGF‑β1/Smads signaling pathway.

  2020cites this paper
• Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants.

  2020cites this paper
• Decreased neutrophil levels in bronchopulmonary dysplasia infants.

  2020cites this paper
• Present and Future of Bronchopulmonary Dysplasia

  2020cites this paper
• Glucocorticoid Treatment for Bronchopulmonary Dysplasia

  2020cites this paper
• Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs

  2020cites this paper
• Role of Nutrition in Prevention of Neonatal Spontaneous Intestinal Perforation and Its Complications: A Systematic Review

  2020cites this paper
• Effects of Liberal vs Restrictive Transfusion Thresholds on Survival and Neurocognitive Outcomes in Extremely Low-Birth-Weight Infants: The ETTNO Randomized Clinical Trial.

  2020cites this paper
• Treatment and respiratory support modes for neonates with respiratory distress syndrome

  2020cites this paper
• [Effect of asiaticoside on hyperoxia-induced bronchopulmonary dysplasia in neonatal rats and related mechanism].

  2020cites this paper
• Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE)

  2020cites this paper
• Dose of budesonide with surfactant affects lung and systemic inflammation after normal and injurious ventilation in preterm lambs

  2020cites this paper
• The impact of inhaled bronchodilators on bronchopulmonary dysplasia: a nonrandomized comparison from the NEuroSIS trial

  2020cites this paper
• Early inhaled budesonide in extremely preterm infants decreases long‐term respiratory morbidity

  2020cites this paper
• Systemic and topical glucocorticoids to prevent BPD

  2020cites this paper
• History of caffeine use in neonatal medicine and the role of the CAP trial.

  2020cites this paper
• L’administration postnatale de corticostéroïdes pour prévenir ou traiter la dysplasie bronchopulmonaire chez les nouveau-nés prématurés

  2020cites this paper
• Pharmacological Therapies for the Prevention of Bronchopulmonary Dysplasia

  2020cites this paper
• Tackling bronchopulmonary dysplasia (BPD) to improve preterm health - A call for family-centered care at World Prematurity Day 2020.

  2020cites this paper
• Bronchopulmonary Dysplasia and Oxidative Stress in the Newborn

  2019cites this paper
• Long‐term effects of the intratracheal administration of corticosteroids for the prevention of bronchopulmonary dysplasia: A meta‐analysis

  2019cites this paper
• Metered‐dose inhaler therapy with spacers: Are newborns capable of using this system correctly?

  2019cites this paper